

Resource Summary Report

Generated by NIF on Aug 1, 2026

MDM2 (SMP14)

RRID:AB_627920

Type: Antibody

Proper Citation

Santa Cruz Biotechnology Cat# sc-965, RRID:AB_627920

Antibody Information

URL: http://antibodyregistry.org/AB_627920

Proper Citation: Santa Cruz Biotechnology Cat# sc-965, RRID:AB_627920

Target Antigen: detection of MDM2, MDM2 p60 cleavage product and p53-MDM2 complexes

Host Organism: mouse

Clonality: monoclonal

Comments: Used By NYUIHC-1282

Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE

Antibody Name: MDM2 (SMP14)

Description: This monoclonal targets detection of MDM2, MDM2 p60 cleavage product and p53-MDM2 complexes

Target Organism: rat, mouse, human

Clone ID: [SMP14]

Antibody ID: AB_627920

Vendor: Santa Cruz Biotechnology

Catalog Number: sc-965

Record Creation Time: 20250819T215204+0000

Record Last Update: 20250820T002112+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for MDM2 (SMP14).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 34 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Zhang D, et al. (2025) FLT3L-based drug conjugate effectively targets chemoresistant leukemia stem cells in acute myeloid leukemia. Cell reports. Medicine, 102365.

Mani R, et al. (2025) TP53 upregulation via aurora kinase inhibition overcomes primary failure to venetoclax in BCL2-rearranged lymphomas. iScience, 28(6), 112584.

Hsieh FS, et al. (2024) Plausible, robust biological oscillations through allelic buffering. Cell systems, 15(11), 1018.

Cordova RA, et al. (2024) Coordination between the eIF2 kinase GCN2 and p53 signaling supports purine metabolism and the progression of prostate cancer. Science signaling, 17(864), eadp1375.

Weinstein HNW, et al. (2024) RPL22 is a tumor suppressor in MSI-high cancers and a splicing regulator of MDM4. Cell reports, 43(8), 114622.

Zong Z, et al. (2024) Alanyl-tRNA synthetase, AARS1, is a lactate sensor and lactyltransferase that lactylates p53 and contributes to tumorigenesis. Cell, 187(10), 2375.

Hu H, et al. (2023) The RNA binding protein RALY suppresses p53 activity and promotes lung tumorigenesis. Cell reports, 42(4), 112288.

Wang X, et al. (2023) Targeting KRAS-mutant stomach/colorectal tumors by disrupting the ERK2-p53 complex. Cell reports, 42(1), 111972.

Zhang L, et al. (2023) A p53/LINC00324 positive feedback loop suppresses tumor growth by counteracting SET-mediated transcriptional repression. Cell reports, 42(8), 112833.

Wu Z, et al. (2023) Coupled deglycosylation-ubiquitination cascade in regulating PD-1 degradation by MDM2. *Cell reports*, 42(7), 112693.

Szwarc MM, et al. (2023) FAM193A is a positive regulator of p53 activity. *Cell reports*, 42(3), 112230.

Mansky RH, et al. (2023) Tumor suppressor p53 regulates heat shock factor 1 protein degradation in Huntington's disease. *Cell reports*, 42(3), 112198.

Pranzini E, et al. (2022) SHMT2-mediated mitochondrial serine metabolism drives 5-FU resistance by fueling nucleotide biosynthesis. *Cell reports*, 40(7), 111233.

Granieri L, et al. (2022) Targeting the USP7/RRM2 axis drives senescence and sensitizes melanoma cells to HDAC/LSD1 inhibitors. *Cell reports*, 40(12), 111396.

Rodriguez-Ramirez C, et al. (2022) p53 Inhibits Bmi-1-driven Self-Renewal and Defines Salivary Gland Cancer Stemness. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 28(21), 4757.

Latif AL, et al. (2021) BRD4-mediated repression of p53 is a target for combination therapy in AML. *Nature communications*, 12(1), 241.

Zampetidis CP, et al. (2021) A recurrent chromosomal inversion suffices for driving escape from oncogene-induced senescence via subTAD reorganization. *Molecular cell*, 81(23), 4907.

Ramos H, et al. (2021) A selective p53 activator and anticancer agent to improve colorectal cancer therapy. *Cell reports*, 35(2), 108982.

Hanson RL, et al. (2020) Rucaparib Treatment Alters p53 Oscillations in Single Cells to Enhance DNA-Double-Strand-Break-Induced Cell Cycle Arrest. *Cell reports*, 33(2), 108240.

Hodel KP, et al. (2020) POLE Mutation Spectra Are Shaped by the Mutant Allele Identity, Its Abundance, and Mismatch Repair Status. *Molecular cell*, 78(6), 1166.